WuXi AppTec

WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time.

Our Vision

Every drug can be made and every disease can be treated

WuXi AppTec

Integrated End-to-End CRDMO Platform

Contact us

400-820-0985 (China)
857-413-2800 (U.S.)
+86 (21) 2066-3734 (Global)

wuxiconcierge@wuxiapptec.com

www.wuxiapptec.com

Follow us on LinkedIn.

WuXi AppTec

WuXi Discovery Services

WuXi AppTec
603259.SH/2359.HK

WuXi AppTec

Integrated End-to-End CRDMO Enabling Platform



WuXi Chemistry

Integrated, end-to-end chemistry research, development, and commercial manufacturing services.



WuXi Biology

A full spectrum of biology services and solutions supporting stand-alone and integrated projects.

WuXi Testing

An integrated testing platform across the full life cycle of discovery and development to deliver innovative medicines to patients.



WuXi AppTec

WuXi Chemistry

A comprehensive CRDMO platform that moves molecules from discovery to market. Capacity and capabilities to support all phases of drug development at any scale for all synthetic molecular modalities.

- **420,000+** compounds (in the past 12 months); **3,452** preclinical, clinical and commercial drugs, commercial and phase III projects increased by **22** during the year. (as of Q4 2025)
- Successful inspections by U.S. FDA, EU EMA, China NMPA, Japan PMDA, South Korea MFDS, and SwissMedic, and over **100** country approvals for branded drugs
- **800+** CMC submission packages written to support global IND and NDA filings from 2019 to 2025

WuXi Research Chemistry Services

Small Molecule Discovery
Medicinal Chemistry | Custom Synthesis | Library | Discovery Process Chemistry

- Delivered 420,000+ compounds (in the past 12 months)
- **Technology Platform**: Reaction Conditions Screening, Photoredox Chemistry, Flow Chemistry, Biocatalysis, Electrochemistry, Computer-Aided Drug Design
- **Specialty Chemistry**: Targeted Covalent Inhibitor, Targeted Protein Degrader, Fluorine Chemistry, Carbohydrate, Macrocycle, Organoboron, Stable Isotope Labeling

WuXi TIDES

Peptide and Oligonucleotide Discovery, Development, Manufacturing
Oligonucleotides | Peptides | Conjugates | Amidites | Unnatural Amino Acids | Linkers | Ligands

- Simplifying TIDES drug development by providing discovery, CMC development and the entire manufacturing supply chain under one roof
- Over 20 oligonucleotide production lines at all scales
- 100,000 L peptide solid phase total reactor volume
- **Novel technology platforms**: Biocatalysis, Thin Film Evaporation, TFF/precipitation, Continuous Purification

WuXi STA

Small Molecule Development and Manufacturing
Drug Substance | Drug Product | Analytical | Regulatory Dossier Preparation

- Approximately 4,000 m^3 total reactor volume for small molecule API and intermediate manufacturing
- **Drug Substance Enabling Technology Portfolio**: Crystallization & Particle Engineering, Biocatalysis, Chemo Catalysis, Flow Chemistry, Preparative HPLC & SFC & SMB, High Potency API
- **Drug Product Enabling Technology Portfolio**: Spray Dried Dispersion, Nano Suspension, Hot Melt Extrusion, Lipid Nanoparticle, High Potency Drug Product
- 5 drug product sites in North America, Europe, and Asia, supporting both oral solid and parenteral dosage forms



WuXi Biology

A comprehensive spectrum of biology services and solutions, supporting stand-alone and integrated projects, from target discovery to hit finding, lead optimization, candidate selection, and beyond.



- **Comprehensive** discovery and translational biology centers, with **~3,000** experienced scientists and global footprints in **8** sites
- Early discovery screening platform, providing diverse **hit finding solutions** and **high throughput hit optimization solutions** such as DEL/HTS/HCS/ASMS/FBDD*/Display/virtual screening and Direct-to-Biology, supported by informatics and data sciences
- **Thousands** of validated, 'ready to go', general assays and *in vitro* and *in vivo* models enabling discovery biology for comprehensive target classes, therapeutic areas and modalities
- Extensive pharmacology services in **oncology, immunology, metabolic disease, neuroscience, cardiovascular disease, infectious disease, and rare diseases**, offering an end-to-end service from discovery, through optimization and into clinical development
- **AAALAC** accredited and **BSL-2** certified on multiple sites
- **CAP-certified** molecular biomarker labs supporting translational and clinical researches

Modalities

- Small molecules
- Peptides & Oligonucleotides
- Conjugates: ADC/AOC/RDC/POC/PDC*…
- TPD* & molecular glues
- Vaccines
- CGT

Early Discovery

- New target discovery and mechanistic study
- Protein production and structural biology
- High throughput hit optimization: D2B platform
- Screening and hit identification： DEL/HTS/ HCS/ASMS/FBDD/Display/VS
- Small molecule & new modality libraries



Compound Profiling

- Comprehensive compound management support
- Biophysics
- *In vitro* biochemistry and cell biology
- Cell panel screening
- MOA studies
- Proteomics

In Vitro & *In Vivo* Pharmacology

- Broad disease model collection
- Translational solutions
- Drug resistance models
- Disease model database
- Full scope PD biomarker analysis

*DEL: DNA-Encoded Library; HTS: High Throughput Screening; HCS: High Content Screening; ASMS: Affinity Selection Mass Spectrometry; FBDD: Fragment-Based Drug Discovery; ADC: Antibody-Drug Conjugate; PDC: Peptide-Drug Conjugate; POC: Peptide-Oligonucleotide Conjugate; TPD: Targeted Protein Degradation

WuXi Testing

An integrated testing platform across the full life cycle of discovery and development to deliver innovative medicines to patients.



- Comprehensive *in vitro* and *in vivo* global DMPK services
- Comprehensive nonclinical services including GLP toxicology and safety pharmacology for successful regulatory approval
- GLP clinical bioanalysis services based on the latest novel technologies

WuXi IND (WIND): An integrated IND service program that includes CMC, preclinical (pharmacology, DMPK, toxicology), clinical bioanalysis and regulatory affairs services

WuXi NDA (WNDA): Long-term toxicology, reproductive and developmental toxicology, developmental DMPK, and clinical bioanalysis services with CMC services that enable customers to move the molecules from IND to NDA/BLA

Our Continued Commitment to Sustainability

As a responsible corporate citizen, WuXi AppTec remains steadfast in its commitment to operating sustainably for the benefit of customers, investors, employees and communities, both now and in the future.

Participant of the United Nations Global Compact for two consecutive years, supporting its ten sustainability principles;

Became a Supplier Partner of the Pharmaceutical Supply Chain Initiative for two consecutive years;

The near-term greenhouse gas emissions reduction targets have been validated by the Science Based Target initiative.

Robust Stainability Governance Structure

The Strategy Committee of the Board of Directors reviews and oversees the Company's sustainability strategies and guiding principles ;
The Sustainability Committee coordinates internal resources to drive implementation and monitor performance.

Uphold Business Ethics and Compliance Standards

We strictly comply with applicable laws and regulations in all operating jurisdictions and adhere to the highest business ethics standards ;
In 2025, **20** main sites obtained ISO/IEC 27001 Information Security Management System certification.

Advance Green and Low-Carbon Development

Taking 2024 as the base year. We commit to reducing absolute Scope 1 and 2 greenhouse gas emissions by **42%** , and absolute Scope 3 greenhouse gas emissions by **25%** by 2030; The share of renewable electricity reached **34%** in 2025

Empower Communities for Sustainability

Leveraging our professional expertise and targeted resource investment, we build long-term collaboration with stakeholders to continuously enhance our corporate social responsibility roadmap and contribute to sustainable social development.

Unwavering Commitment to Customers' IP and the Highest Quality & Compliance Standards

741[1]
Quality Audits & Inspections by Global Customers, Regulatory Authorities and Third Parties in 2025

0
Critical Finding

IP
ZERO TOLERANCE

60
Information Security Audits by Global Customers in 2025

20[2]
Main Sites are **ISO/IEC 27001 Certified**

Note: 1. Including 680 audits by customers, 56 inspections by regulatory authorities, and 5 audits by independent third parties.
2. Including all the main sites in China or Continuing 0perations (not including clinical service business).

Robust Data Privacy and Security System

Data security and privacy protection are among our highest priorities. Since our founding, WuXi AppTec has maintained a strong track record of data privacy based on rigorous security processes. Everything we discover, develop and deliver to our customers is secure, separated and protected.

Adhering to Global Regulatory Standards

- CMC platform (drug substance, drug product, analytical and regulatory CMC support) received FDA approval for New Chemical Entities
- CDMO approved by regulatory agencies in U.S., Canada, EU, Switzerland, China, Australia and New Zealand to supply APIs, GMP intermediates for branded commercial drugs
- First CDMO to support the approval of an innovative drug in China through the Marketing Authorization Holder ("MAH") pilot program
- GLP toxicology laboratory certified by both OECD and NMPA, and passed FDA and NMPA inspections
- GLP/GCP bioanalytical laboratory passed FDA, OECD, NMPA and PMDA inspections

National Medical Products Administration · Australian Government Department of Health and Aged Care Therapeutic Goods Administration · Health Canada · OECD · swissmedic Swiss Agency for Therapeutic Products · FDA U.S. Food & Drug Administration · Pmda · European Medicines Agency · Ministry for Primary Industries Manatū Ahu Matua · Saudi Food & Drug Authority

Fighting Diseases by Enabling High-Quality Medicines Faster

Advanced development of therapy approved by FDA and NMPA for the treatment of adult patients with **chronic hepatitis C virus genotypes 1 and 4 infections**

Advanced development of first oral-targeted therapy approved by FDA for the treatment of adult patients with **relapsed or refractory acute myeloid leukemia** with an isocitrate dehydrogenase-2 mutation

Supported the development of the first oral therapy approved by FDA and NMPA for the treatment of patients with **chronic lymphocytic leukemia, mantle cell lymphoma and Waldenström's macroglobulinemia**

Supported the acquisition of implied license of clinical trial from FDA for a small molecule drug for the treatment of **Alzheimer's Disease**

Provided all-round support for a BTK inhibitor to receive accelerated NDA approval for treatment of **mantle cell lymphoma** from FDA

Expedited an NDA submission to receive FDA approval for a breakthrough treatment of **ovarian cancer**

Awards and Industry Recognition Partially Listed

Industry Leadership	Frost & Sullivan: Global Contract Research Development and Manufacturing Organization Company of the Year (2022-2025)	TIME World's Best Companies 2025: TIME magazine's "World's Best Companies in Sustainable Growth 2025	Fortune: Ranked among "The Future 50" (2020-2021)	MIT Technology Review: 50 Smartest Companies (2019)
	C&EN: Company of the Year (2018)	ACS Chemistry for Life: Heroes of Chemistry Award (2017)	Scrip Pharma Intelligence: Best Company in an Emerging Market (2014)	
Sustainability Rating Performance	MSCI ESG Ratings AAA: Received MSCI ESG "AAA" Leader Rating in 2025	CDP A List 2025 (Climate) · CDP A List 2025 (Water): Received double "A" rating from CDP for Climate Change and Water Security (2025)	EcoVadis Gold: Gold Medal awarded in EcoVadis sustainability rating (2024-2025)	



A Global Footprint



China

Shanghai	R&D Headquarters / Drug Discovery and Preclinical	
Jinshan (Shanghai)	Small Molecule R&D and Manufacturing	
Changzhou	Small Molecule R&D and Manufacturing	
Suzhou	Drug Safety Evaluation	
Nanjing	DMPK and Bioanalytical	
Nantong	Small Molecule R&D	
Taixing	Small Molecule R&D and Manufacturing	
Changshu	Small Molecule R&D and Manufacturing	
Wuxi	Small Molecule Manufacturing	
Tianjin	Chemistry and Drug Discovery	
Chengdu	Drug Discovery and Preclinical	
Wuhan	Chemistry and Drug Discovery	
Beijing	Program Management	

South Korea

Pan-Gyo	Program Management

U.S.

Boston / Natick	MA	Compound Management / Logistics Center / Program Management
Cranbury	NJ	DMPK and Biology
San Diego	CA	Biology / Small Molecule Process Development and Manufacturing
Middletown	DE	Small Molecule Manufacturing

Germany

Munich	Drug Discovery /Biology

Switzerland

Couvet	Small Molecule Manufacturing

Singapore

Singapore	Small Molecule R&D and Manufacturing

Japan

Kyoto	BD / Program Management

**Statistics as of Q4 2025 (December 31, 2025)